Intertek Acquires Melbourn - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Intertek Acquires Melbourn
The acquisition of Melbourn extends Intertek's offering to include formulation, product development and characterisation of orally inhaled and intranasal products amongst others.

Intertek has acquired Melbourn Scientific Ltd, a provider of analysis and development services for the pharmaceutical, biopharmaceutical, biotechnology and healthcare industries, based in Royston, near Cambridge, UK.

Melbourn offers a range of services to support the global pharmaceutical and healthcare industry including formulation and product development, analytical method development and validation, stability studies and QC release testing. In addition to services for conventionally delivered medicines, the company has expertise in characterization of orally inhaled and intranasal products (OINDP) and transdermal devices.

Patient-friendly drug-delivery methods have been gaining popularity as a means to achieve optimum therapeutic efficacy and efficiency as well as enhanced patient outcomes. Melbourn’s formulation services include reformulation of existing products to improve efficacy or extend patent life and to widen the market potential for a given product. As an example, reformulating an injection into an oral inhalation product is a key strategy of many global pharmaceutical majors to achieve increased market share by improving bioavailability and drug use uptake within a patient population (i.e., by improving delivery at the target) whilst reducing patient trauma.

Melbourn’s 20,000-square-feet facility complies with GMP standards and is regularly inspected by the UK Medicines and Health Regulatory Authority (MHRA) and the FDA.

Dr. Andrew Swift, vice-president of Intertek Chemicals and Pharmaceuticals, said in a press statement that combining the company’s capabilities for measuring device and drug interaction with Melbourn’s expertise in OINDP drug characterization would provide a unique offering to support drug development.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here